Depending on the dose, maintenance upadacitinib (Rinvoq) either doubled or tripled clinical remissions at 1 year in patients with moderately to severely active Crohn's disease, the phase III

U-ENDURE trial showed.

In an intention-to-treat analysis involving over 500 patients who had initially responded to induction therapy with the Janus kinase (JAK) inhibitor, clinical remission was observed in 47.6%

of the 30-mg upadacitinib group and 37.3% of the 15-mg group, as compared with 15.1% of placebo patients (P